BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Amal M.H. Mackawy, Mohammed E.H. Badawy, Ola Abd El-Rahman Yossef Megahed. Angiotensin converting enzyme (ACE D/I) polymorphism and its relation to liver fibrosis progression in Egyptian patients with chronic hepatitis C virus infectionEgyptian Journal of Medical Human Genetics 2012; 13(3): 291 doi: 10.1016/j.ejmhg.2012.06.006
2
J.S. Lubel, F.J. Warner, P.W. Angus. Frontiers in Research of the Renin-Angiotensin System on Human DiseaseProteases in Biology and Disease 2008; 7: 113 doi: 10.1007/978-1-4020-6372-5_6
3
Qiu-Zan Zhang, Ying-Li Liu, Yan-Rong Wang, Li-Na Fu, Jing Zhang, Xiu-Ru Wang, Bang-Mao Wang. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver diseaseExperimental and Therapeutic Medicine 2017; 14(3): 2689 doi: 10.3892/etm.2017.4809
4
A. Mantovani, G. Zoppini, G. Targher, G. Golia, E. Bonora. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individualsJournal of Endocrinological Investigation 2012; 35(2): 215 doi: 10.1007/BF03345421
5
Brent A Neuschwander-Tetri. Fatty liver and the metabolic syndromeCurrent Opinion in Gastroenterology 2007; 23(2): 193 doi: 10.1097/MOG.0b013e32801421a9
6
Dawn M. Torres, Frances J. Jones, Janet C. Shaw, Christopher D. Williams, John A. Ward, Stephen A. Harrison. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trialHepatology 2011; 54(5): 1631 doi: 10.1002/hep.24558
7
Dawn M. Torres, Stephen A. Harrison. Current treatments in nonalcoholic steatohepatitisCurrent Treatment Options in Gastroenterology 2007; 10(6): 425 doi: 10.1007/s11938-007-0042-y
8
James Neuberger. Zakim and Boyer's Hepatology2012; : 910 doi: 10.1016/B978-1-4377-0881-3.00051-6
9
Erika Rabelo F Siqueira. A Review of Pharmacological Treatments of NASHGastroenterology & Hepatology: Open Access 2015; 2(5) doi: 10.15406/ghoa.2015.02.00058
10
Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Shinsuke Masubuchi, Maiko Ozeki, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol dietExperimental Animals 2018; 67(2): 239 doi: 10.1538/expanim.17-0126
11
Mariko Hojo, Sumio Watanabe. Pharmacological therapy of nonalcoholic steatohepatitisHepatology Research 2011; 41(3): 209 doi: 10.1111/j.1872-034X.2011.00780.x
12
Thuy-Anh Le, Rohit Loomba. Management of Non-alcoholic Fatty Liver Disease and SteatohepatitisJournal of Clinical and Experimental Hepatology 2012; 2(2): 156 doi: 10.1016/S0973-6883(12)60104-2
13
O. Guillaud, K.C. Gurram, M. Puglia, L. Lilly, O. Adeyi, E.L. Renner, N. Selzner. Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver TransplantationTransplantation Proceedings 2013; 45(6): 2331 doi: 10.1016/j.transproceed.2013.01.067
14
Matthew J. Brookes, Tariq H. Iqbal, Brian T. Cooper. Hypertension and hepatic steatosisCurrent Hypertension Reports 2008; 10(3): 182 doi: 10.1007/s11906-008-0035-9
15
Palanivelu Praveenraj, Rachel M. Gomes, Saravana Kumar, Purushothaman Karthikeyan, Annapoorni Shankar, Ramakrishnan Parthasarathi, Palanisamy Senthilnathan, Subbiah Rajapandian, Chinnusamy Palanivelu. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric SurgeryObesity Surgery 2015; 25(11): 2078 doi: 10.1007/s11695-015-1655-1
16
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief reviewHypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
17
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic optionsClinical Science 2012; 123(4): 225 doi: 10.1042/CS20120030
18
Zhaoyang Ye, Houssam S. Hajj Houssein, Ram I. Mahato. Bioconjugation of Oligonucleotides for Treating Liver FibrosisOligonucleotides 2007; 17(4): 349 doi: 10.1089/oli.2007.0097
19
Stergios A. Polyzos, Jannis Kountouras, Christos Zavos, Eleni Tsiaousi. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism 2010; 12(5): 365 doi: 10.1111/j.1463-1326.2009.01176.x
20
Ahad Eshraghian. Current and emerging pharmacological therapy for non-alcoholic fatty liver diseaseWorld Journal of Gastroenterology 2017; 23(42): 7495-7504 doi: 10.3748/wjg.v23.i42.7495
21
Kenneth Cusi. Nonalcoholic fatty liver disease in type 2 diabetes mellitusCurrent Opinion in Endocrinology, Diabetes and Obesity 2009; 16(2): 141 doi: 10.1097/MED.0b013e3283293015
22
Phunchai Charatcharoenwitthaya, Jayant A. Talwalkar, Paul Angulo, Andrea A. Gossard, Jill C. Keach, Janice L. Petz, Roberta A. Jorgensen, Keith D. Lindor. Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic AcidDigestive Diseases and Sciences 2010; 55(2): 476 doi: 10.1007/s10620-009-0744-1
23
Eugen Florin Georgescu. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?Advances in Therapy 2008; 25(11): 1141 doi: 10.1007/s12325-008-0110-2
24
Maria Soledad Rosselli, Adriana L. Burgueño, Julieta Carabelli, Mariano Schuman, Carlos J. Pirola, Silvia Sookoian. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease modelAtherosclerosis 2009; 206(1): 119 doi: 10.1016/j.atherosclerosis.2009.01.026
25
Yosui Tamaki, Yukiomi Nakade, Taeko Yamauchi, Yuichi Makino, Shiro Yokohama, Mitsuyoshi Okada, Kazunobu Aso, Hiroyuki Kanamori, Tomohiko Ohashi, Ken Sato, Haruhisa Nakao, Masakazu Haneda, Masashi Yoneda. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitisJournal of Gastroenterology 2013; 48(4): 491 doi: 10.1007/s00535-012-0651-7
26
Simone Moreira de Macêdo, Talita Antunes Guimarães, John David Feltenberger, Sérgio Henrique Sousa Santos. The role of renin-angiotensin system modulation on treatment and prevention of liver diseasesPeptides 2014; 62: 189 doi: 10.1016/j.peptides.2014.10.005
27
Takeshi Okanoue, Atsushi Umemura, Kohichiroh Yasui, Yoshito Itoh. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in JapanJournal of Gastroenterology and Hepatology 2011; 26: 153 doi: 10.1111/j.1440-1746.2010.06547.x
28
M Kamruzzman Munshi, Mohammad N Uddin, Shannon S Glaser. The role of the renin–angiotensin system in liver fibrosisExperimental Biology and Medicine 2011; 236(5): 557 doi: 10.1258/ebm.2011.010375
29
Ping Lu, Hailin Liu, Hang Yin, Liu Yang. Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cellsMedical Science Monitor 2011; 17(9): BR248 doi: 10.12659/MSM.881928
30
S. Kaser, C. F. Ebenbichler, H. Tilg. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver diseaseInternational Journal of Clinical Practice 2010; 64(7): 968 doi: 10.1111/j.1742-1241.2009.02327.x
31
Claudia Della Corte, Anna Alisi, Raffaele Iorio, Arianna Alterio, Valerio Nobili. Expert opinion on current therapies for nonalcoholic fatty liver diseaseExpert Opinion on Pharmacotherapy 2011; 12(12): 1901 doi: 10.1517/14656566.2011.587123
32
Mariana Machado, Helena Cortez-Pinto. Non-alcoholic steatohepatitis and metabolic syndromeCurrent Opinion in Clinical Nutrition and Metabolic Care 2006; 9(5): 637 doi: 10.1097/01.mco.0000241677.40170.17
33
Rafeeq Ali, Kenneth Cusi. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)Annals of Medicine 2009; 41(4): 265 doi: 10.1080/07853890802552437
34
Shivakumar Chitturi. Review: Treatment options for nonalcoholic fatty liver diseaseTherapeutic Advances in Gastroenterology 2008; 1(3): 173 doi: 10.1177/1756283X08096951
35
MH Ahmed, CD Byrne. Drug treatment and type 2 diabetes: the impact of liver diseasePractical Diabetes International 2007; 24(6): 318 doi: 10.1002/pdi.1132
36
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitisHepatology Research 2015; 45(4): 363 doi: 10.1111/hepr.12511
37
Bilal Hameed, Norah Terrault. Emerging Therapies for Nonalcoholic Fatty Liver DiseaseClinics in Liver Disease 2016; 20(2): 365 doi: 10.1016/j.cld.2015.10.015
38
Vlad Ratziu, Maria Vispo, Mohamed Tahiri, Luminita Bonyhay, Mercedes de Torres, Carole Bernhardt, Thierry Poynard, Pascal Lebray. Peut-on traiter la stéatohépatite métabolique ?Gastroentérologie Clinique et Biologique 2007; 31(3): 333 doi: 10.1016/S0399-8320(07)89386-9
39
S. Strahl, K.P. Maier. Gibt es Therapieansätze für die nicht-alkoholische Fettleber und ihre Komplikationen?Der Internist 2008; 49(12): 1421 doi: 10.1007/s00108-008-2151-7
40
Vlad Ratziu, Shira Zelber-Sagi. Pharmacologic Therapy of Non-Alcoholic SteatohepatitisClinics in Liver Disease 2009; 13(4): 667 doi: 10.1016/j.cld.2009.07.001
41
Takumi Hirata, Kengo Tomita, Toshihide Kawai, Hirokazu Yokoyama, Akira Shimada, Masahiro Kikuchi, Hiroshi Hirose, Hirotoshi Ebinuma, Junichiro Irie, Keisuke Ojiro, Yoichi Oikawa, Hidetsugu Saito, Hiroshi Itoh, Toshifumi Hibi. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)International Journal of Endocrinology 2013; 2013: 1 doi: 10.1155/2013/587140
42
Kannan Sridharan, Gowri Sivaramakrishnan, Reginald Paul Sequeira, Abdelaziz Elamin. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysisPostgraduate Medical Journal 2018; 94(1116): 556 doi: 10.1136/postgradmedj-2018-135967
43
Fiona J. Warner, John S. Lubel, Geoffrey W. McCaughan, Peter W. Angus. Liver fibrosis: a balance of ACEs?Clinical Science 2007; 113(3): 109 doi: 10.1042/CS20070026
44
Keisuke Okamura, Tetsu Okuda, Yosuke Takamiya, Kazuyuki Shirai, Hidenori Urata. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytesHeart and Vessels 2019; 34(9): 1559 doi: 10.1007/s00380-019-01391-4
45
Carlo Fabris, Carlo Smirne, Stefano Fangazio, Pierluigi Toniutto, Michela Burlone, Rosalba Minisini, Davide Bitetto, Edmondo Falleti, Andrea Cerutti, Mario Pirisi. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis CHepatology Research 2009; 39(8): 795 doi: 10.1111/j.1872-034X.2009.00518.x
46
Marko Duvnjak, Neven Baršić, Vedran Tomašić, Ivan Lerotić. Genetic polymorphisms in non-alcoholic fatty liver disease: Clues to pathogenesis and disease progressionWorld Journal of Gastroenterology 2009; 15(48): 6023-6027 doi: 10.3748/wjg.15.6023
47
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertensionThe Korean Journal of Internal Medicine 2018; 33(3): 453 doi: 10.3904/kjim.2017.317
48
Yasuhiro Miyake, Kazuhide Yamamoto. Role of gut microbiota in liver diseasesHepatology Research 2013; 43(2): 139 doi: 10.1111/j.1872-034X.2012.01088.x
49
Jung Gyu Park, Jong Soo Mok, Young In Han, Tae Sub Park, Keon Wook Kang, Cheol Soo Choi, Hee Dong Park, Joonghoon Park. Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by TelmisartanScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-40322-1
50
J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, P. N. Newsome. Current therapeutic strategies in non-alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism 2011; 13(8): 692 doi: 10.1111/j.1463-1326.2011.01403.x
51
Lindsey J. Reese, Diane S. Tider, Alicia C. Stivala, Dawn A. Fishbein. Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C CoinfectionAIDS Research and Treatment 2012; 2012: 1 doi: 10.1155/2012/978790
52
Ka-Kit Li, James Neuberger. Recurrent nonviral liver disease following liver transplantationExpert Review of Gastroenterology & Hepatology 2009; 3(3): 257 doi: 10.1586/egh.09.16
53
Grace Hui-Min Wu, Barbara J Boucher, Yueh-Hsia Chiu, Chao-Sheng Liao, Tony Hsiu-Hsi Chen. Impact of chewing betel-nut (Areca catechu) on liver cirrhosis and hepatocellular carcinoma: a population-based study from an area with a high prevalence of hepatitis B and C infectionsPublic Health Nutrition 2009; 12(1): 129 doi: 10.1017/S1368980008002073
54
David van der Poorten, Jacob George. Current and novel therapies for the treatment of nonalcoholic steatohepatitisHepatology International 2007; 1(3): 343 doi: 10.1007/s12072-007-9011-8
55
Eugen Florin Georgescu, Reanina Ionescu, Mihaela Niculescu, Laurentiu Mogoanta, Liliana Vancica. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitisWorld Journal of Gastroenterology 2009; 15(8): 942-954 doi: 10.3748/wjg.15.942
56
KASL clinical practice guidelines: Management of nonalcoholic fatty liver diseaseClinical and Molecular Hepatology 2013; 19(4): 325 doi: 10.3350/cmh.2013.19.4.325
57
John S Lubel, Chandana B Herath, Louise M Burrell, Peter W Angus. Liver disease and the renin-angiotensin system: Recent discoveries and clinical implicationsJournal of Gastroenterology and Hepatology 2008; 23(9): 1327 doi: 10.1111/j.1440-1746.2008.05461.x
58
William Peverill, Lawrie Powell, Richard Skoien. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and InflammationInternational Journal of Molecular Sciences 2014; 15(5): 8591 doi: 10.3390/ijms15058591
59
Paul Manka, Amos Zeller, Wing-Kin Syn. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment ModalitiesDrugs 2019; 79(9): 903 doi: 10.1007/s40265-019-01126-9
60
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitisJournal of Gastroenterology 2015; 50(4): 364 doi: 10.1007/s00535-015-1050-7
61
John Richard, Ildiko Lingvay. Hepatic steatosis and Type 2 diabetes: current and future treatment considerationsExpert Review of Cardiovascular Therapy 2011; 9(3): 321 doi: 10.1586/erc.11.15
62
S. Gitto, G. Vitale, E. Villa, P. Andreone. Treatment of Nonalcoholic Steatohepatitis in Adults: Present and FutureGastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/732870
63
Diana Barb, Paola Portillo-Sanchez, Kenneth Cusi. Pharmacological management of nonalcoholic fatty liver diseaseMetabolism 2016; 65(8): 1183 doi: 10.1016/j.metabol.2016.04.004
64
Barham K. Abu Dayyeh, May Yang, Jules L. Dienstag, Raymond T. Chung. The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial CohortDigestive Diseases and Sciences 2011; 56(2): 564 doi: 10.1007/s10620-010-1507-8
65
T. T. Gordon-Walker, A. Pellicoro, J. P. Iredale. Liver under Constant Attack — From Fat to Viruses2009; : 141 doi: 10.1007/978-90-481-2759-7_15
66
Dawn M. Torres, Stephen A. Harrison. Diagnosis and Therapy of Nonalcoholic SteatohepatitisGastroenterology 2008; 134(6): 1682 doi: 10.1053/j.gastro.2008.02.077
67
J. S. Lubel, C. B. Herath, E. Velkoska, D. J. Casley, L. M. Burrell, P. W. Angus. Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture researchCytotechnology 2008; 58(3): 119 doi: 10.1007/s10616-009-9185-0
68
Mariana Verdelho Machado, Helena Cortez-Pinto. Non-alcoholic fatty liver disease: What the clinician needs to knowWorld Journal of Gastroenterology 2014; 20(36): 12956-12980 doi: 10.3748/wjg.v20.i36.12956
69
Mariana Machado, Pedro Marques-Vidal, Helena Cortez-Pinto. Hepatic histology in obese patients undergoing bariatric surgeryJournal of Hepatology 2006; 45(4): 600 doi: 10.1016/j.jhep.2006.06.013